VEA
VIR icon

Virtus ETF Advisers’s Vir Biotechnology VIR Stock Holding History

Virtus ETF Advisers’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,568
Closed -$70.2K – 790
2024
Q4 		$70.2K Buy
9,568
+674
+8% +$5.32K 0.03% 377
2024
Q3 		$66.6K Buy
8,894
+156
+2% +$1.35K 0.03% 433
2024
Q2 		$77.8K Buy
8,738
+108
+1% +$1.04K 0.04% 417
2024
Q1 		$87.4K Sell
8,630
-591
-6% -$6.02K 0.05% 385
2023
Q4 		$92.8K Buy
9,221
+5,419
+143% +$49.5K 0.06% 393
2023
Q3 		$35.6K Sell
3,802
-377
-9% -$5.38K 0.02% 424
2023
Q2 		$103K Buy
4,179
+274
+7% +$6.88K 0.06% 370
2023
Q1 		$90.9K Sell
3,905
-1,503
-28% -$38.4K 0.05% 361
2022
Q4 		$137K Buy
5,408
+713
+15% +$17.5K 0.07% 373
2022
Q3 		$91K Buy
4,695
+36
+0.8% +$915 0.04% 424
2022
Q2 		$119K Buy
4,659
+1,285
+38% +$30K 0.04% 388
2022
Q1 		$87K Sell
3,374
-194
-5% -$5.75K 0.04% 324
2021
Q4 		$149K Sell
3,568
-1,096
-23% -$42.9K 0.06% 352
2021
Q3 		$203K Sell
4,664
-248
-5% -$10.7K 0.09% 265
2021
Q2 		$232K Sell
4,912
-4,302
-47% -$196K 0.1% 239
2021
Q1 		$472K Buy
9,214
+170
+2% +$9.16K 0.2% 154
2020
Q4 		$242K Buy
9,044
+43
+0.5% +$1.4K 0.1% 322
2020
Q3 		$309K Sell
9,001
-1,225
-12% -$52.7K 0.16% 214
2020
Q2 		$419K Buy
+10,226
New +$343K 0.2% 183

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Virtus ETF Advisers's VIR Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Vir Biotechnology (VIR) in Q1 2025, closing a stake of 9,568 shares — an estimated $70.2K sold.

Virtus ETF Advisers first reported a position in VIR in Q2 2020 and held it in 19 quarters. The position peaked at $472K in Q1 2021. 233 funds tracked by Wall St. Rank hold VIR as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Vir Biotechnology position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 9,568 Vir Biotechnology shares in Q1 2025, an estimated $70.2K.
  • Virtus ETF Advisers first reported a position in Vir Biotechnology in Q2 2020 and held it in 19 quarters.
  • Virtus ETF Advisers's Vir Biotechnology position peaked at $472K in Q1 2021.
  • 233 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.